Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 8/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 3/20 | 0.34 |
| ▸ | PIKFYVE | Q9Y2I7 | 3/20 | 0.34 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
| ▸ | GCKR | Q14397 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | LYN | P07948 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29236495 | 0.74 | NOS3 (0.31) | — | |
| SCHEMBL3586009 | 0.72 | CASP1 (0.42) | TTBK1PGK1PAK4GCKGCKR | |
| SCHEMBL4618985 | 0.71 | LCK (0.35) | — | |
| SCHEMBL21604785 | 0.71 | KDM4E (0.40) | KMT2A | |
| SCHEMBL3576456 | 0.71 | PTPN1 (0.33) | PTPN11 | |
| SCHEMBL30966825 | 0.70 | PTPN11 (0.43) | PGK1PTPN11 | |
| SCHEMBL29236509 | 0.70 | PTPN11 (0.43) | PGK1PTPN11 | |
| SCHEMBL14107967 | 0.69 | MAP4K4 (0.31) | KMT2A | |
| SCHEMBL3570374 | 0.69 | CHRNB2 (0.42) | TTBK1PAK4PIKFYVEPAK1PKN1 | |
| SCHEMBL18034675 | 0.69 | TTBK1 (0.43) | TTBK1PAK4PIKFYVEMAP3K14CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1893605-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103449-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | TIE1, TEK, FLT1 | TTBK1 2104/4885PGK1 3605/4885PAK4 2789/4885 |
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | TTBK1 405/4885PGK1 2356/4885PAK4 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.